# Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer

> **NCT07662031** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 25 (estimated)

## Conditions studied

- Colorectal Cancer
- Metastatic Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Tovecimig
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **DRUG:** 5-Fluorouracil (5-FU)

## Key facts

- **NCT ID:** NCT07662031
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2030-08-31
- **Final completion:** 2032-08-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662031, "Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07662031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*